There were no changes in the NAFLD fibrosis score, APRI score, or FLI after the intervention, whereas the biomarkers, CK-18, and sTLR-4 were reduced in both. The gene discussed is KRT18; the disease is metabolic dysfunction-associated steatotic liver disease.